Description

CJC-1295 + Ipamorelin 10 mg (RUO) · ≥99% HPLC

CJC-1295 Ipamorelin Researcg

CJC-1295 + Ipamorelin 10 mg — Research Overview (RUO)

CJC-1295 + Ipamorelin 10 mg research peptide blend supplied as a lyophilized vial (≥99% HPLC purity; LC–MS identity). For laboratory research only.

GH-Axis & Secretagogue Models

In preclinical endocrine models, CJC-1295 (GHRH analogue) paired with Ipamorelin (GHRP) is investigated for effects on pituitary signaling and growth-hormone secretagogue pathways, including pulsatility and downstream biomarker readouts.

Receptor & Signaling Pathways

Laboratory work has explored engagement of GHRH and GHSR (ghrelin) pathway components, second-messenger signaling, and time-course receptor activation under controlled conditions.

Cellular & Molecular Endpoints

Studies in vitro evaluate endpoints such as receptor expression, signal transduction, and gene/protein markers associated with GH-axis modulation in cell-based assays.

Tissue & Metabolic Research Context

In model systems, the blend has been examined alongside markers tied to protein synthesis, ECM turnover, and energy-signaling pathways, providing reference data for mechanistic research (not clinical use).

Assay/Method Considerations

Common approaches include ELISA/chemiluminescent hormone panels, western blot/qPCR for pathway markers, and time-course sampling to characterize pulsatile responses in vitro or in preclinical designs.

Compliance: Research Use Only (RUO). Not for human or veterinary use. No dosage or administration guidance is provided or implied.

CJC-1295 & Ipamorelin Peptide Blend

Ipamorelin and CJC-1295 are both considered to be growth hormone secretagogues. Ipamorelin is a synthetic pentapeptide,⁽¹⁾ and CJC-1295 peptide consists of 29 amino acids.⁽²⁾ Ipamorelin appears to fall into a category of peptides classified as growth hormone secretagogues (GHSs). These are peptides that are assumed to stimulate the release of the growth hormones, however are not considered growth hormone releasing peptides themselves. On the other hand, CJC-1295 has also been suggested by researchers to stimulate the release of growth hormone, primarily by mimicking the actions of the naturally occurring growth hormone-releasing hormone (GHRH). Both Ipamorelin and CJC-1295 peptides have been assigned by researchers to this class, studied for similar potential actions and apparently differing only in terms of their half-life and pharmacokinetic profiles.

CJC-1295 & Ipamorelin peptides both are suggested by researchers to augment the levels of the growth hormones through a possible triggering of the anterior pituitary gland. Scientists consider that once triggered, growth hormones may be naturally secreted, maintaining levels of growth hormones in the organism.⁽³⁾

References:

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
2. Lucie Jette et al, hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog, ResearchGate, January 2005.
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822 https://pubmed.ncbi.nlm.nih.gov/9849822/
4. The Discovery of Growth Hormone-Releasing Hormone: An Update https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x